Join us for an insightful session on March 27th, featuring the first authors behind three influential 2025 papers on tertiary lymphoid structures (TLS) in cancer:
Masataka Amisaki, MD, PhD, MSKCC (USA)
Presenting a groundbreaking 2025 Nature paper, “IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer”. Dr. Amisaki’s work deepens our understanding of TLS biology and paves the way for innovative therapeutic strategies for transforming “cold” tumors into immunologically active environments.
Florent Peyraud, MD, PhD, Institut Bergonié (France)
Sharing findings from his PhD research, conducted at Explicyte, Dr. Peyaud will discuss 2 publications:
- A research paper in Cell Reports Medicine titled “Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures”
- A comprehensive review in Med. titled “Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside”
Session Introduction
Immunologist Alban Bessede, PhD, CEO of Explicyte, will kick off the session. Dr Bessede has been working on TLS since 2020, co-authoring foundational papers in Nature Cancer and Nature Medicine on TLS & immune-checkpoint inhibitors, and is now developing accredited pathology services for detecting and scoring TLS in tumor specimens to support precision oncology initiatives.